AbbVie Inc.

ABBV · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.1%

Institutions77.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$61.16B	$56.33B	$54.32B	$58.05B	$56.20B	$45.80B	$33.27B	$32.75B	$28.22B	$25.64B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$18.20B	$16.90B	$20.41B	$17.41B	$17.45B	$15.39B	$7.44B	$7.72B	$7.04B	$5.83B
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$15.07B	$9.14B	$12.76B	$18.12B	$17.92B	$11.36B	$12.98B	$6.38B	$9.59B	$9.38B
Operating income as a percentage of revenue.	24.6%	16.2%	23.5%	31.2%	31.9%	24.8%	39.0%	19.5%	34.0%	36.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$7.00M	$8.00M	$10.00M	$9.00M	$7.00M	$6.00M	$7.88B	$5.69B	$5.31B	$5.95B
Net income divided by the number of shares outstanding — profit attributable to each share.	$2.37	$2.40	$2.73	$6.65	$6.48	$2.73	$5.30	$3.00	$3.00	$3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$2.36	$2.39	$2.72	$6.63	$6.45	$2.72	$5.28	$3.00	$3.00	$3.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$5.23B	$5.52B	$12.81B	$9.20B	$9.75B	$8.45B	$39.92B	$7.29B	$9.30B	$5.10B
Everything the company owns that has value — cash, property, inventory, investments, and more.	$133.96B	$135.16B	$134.71B	$138.81B	$146.53B	$150.56B	$89.11B	$59.35B	$70.79B	$66.10B
All of the company's interest-bearing borrowings, short and long term combined.	$2.50B	–	$0	$1.00M	$14.00M	$34.00M	$0	$3.70B	$400.00M	$377.00M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$3.27B	$3.33B	$10.36B	$17.25B	$15.41B	$13.08B	-$8.17B	-$8.45B	$5.10B	$4.64B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$19.03B	$18.81B	$22.84B	$24.94B	$22.78B	$17.59B	$13.32B	$13.43B	$9.96B	$7.04B
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.21B	$974.00M	$777.00M	$695.00M	$787.00M	$798.00M	$552.00M	$638.00M	$529.00M	$479.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$17.82B	$17.83B	$22.06B	$24.25B	$21.99B	$16.79B	$12.77B	$12.79B	$9.43B	$6.56B

	You	Peer avg
P/E	71.0	24.4
Revenue Growth	+10.2%	+3042.7%
ROE	–	-10.2%

AbbVie Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison